Author:
Balakirouchenane David,Khoudour Nihel,Guégan Sarah,Kramkimel Nora,Franck Nathalie,Rodier Thomas,Goldwasser François,Dupin Nicolas,Aractingi Selim,Vidal Michel,Blanchet Benoit
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference20 articles.
1. Five-year outcomes with Dabrafenib plus trametinib in metastatic melanoma;Robert;N. Engl. J. Med.,2019
2. Clinical pharmacokinetics and pharmacodynamics of Dabrafenib;Puszkiel;Clin. Pharmacokinet.,2019
3. Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Tafinlar (dabrafenib);European Medicines Agency,2013
4. Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Mekinist (trametinib);European Medicines Agency,2014
5. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma;Ouellet;Cancer Chemother. Pharmacol.,2016
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献